--- a
+++ b/clusters/3009knumclusters/clust_294.txt
@@ -0,0 +1,200 @@
+Amylase and lipase =< 1.5 x ULN without any symptoms of pancreatitis
+PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum lipase and amylase < 1.5 x ULN, within 2 weeks prior to enrollment
+PARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum lipase and amylase < 1.5 x ULN, within 2 weeks prior to enrollment
+Serum lipase =< ULN at baseline; patients with glucose intolerance should be on a stable regimen and be monitored
+Serum amylase =< 1.5 x ULN
+Serum lipase =< 1.5 x ULN
+Patients must have amylase or lipase within =< 1.5 x IULN without symptoms of pancreatitis at registration, within 28 days prior to registration
+Serum amylase =< 1.5 ULN
+Serum lipase =< 1.5 ULN
+Lipase: 1.5 x ULN. Subjects with lipase >1.5 x ULN may enrol if there are neither clinical or radiographic signs of pancreatitis
+Amylase: 1.5 x ULN. Subjects with amylase >1.5 x ULN may enrol if there are neither clinical or radiographic signs of pancreatitis
+Serum pancreatic amylase < 1.5 x ULN
+Serum pancreatic lipase < 1.5 x ULN
+Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis, within 14 days before the first dose of cabozantinib
+Serum lipase and amylase =< 1.5 x ULN
+Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis within 7 days before the first dose of cabozantinib
+Amylase/lipase =< 1.5 x institutional ULN (without symptoms of pancreatitis)
+Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
+EXCLUSION - INFUSION: Lipase > 70 U/ml
+Asymptomatic serum amylase =< grade 2 and asymptomatic serum lipase =< grade 2; patients with grade 1 or grade 2 serum amylase or lipase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.), at the screening visit
+Asymptomatic serum amylase =< 2 x ULN; patients with > ULN but =< 2 x ULN serum amylase at study start must be confirmed to have no signs and/or symptoms suggestion pancreatitis or pancreatic injury (e.g. elevated pancreatic [P]-amylase, abnormal imaging findings of pancreas, etc.)
+Serum lipase =< ULN
+History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
+Amylase =< 1 x ULN.
+Lipase =< 1 x ULN.
+Amylase and lipase =< 2 x ULN
+Serum amylase =< 1.5 X institutional ULN
+Lipase =< 1.5 X institutional ULN
+Obtained within 28 days prior to the first dose of cabozantinib: lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis.
+Amylase and lipase < 1.5 x ULN obtained ? 14 days prior to randomization
+Lipase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
+Amylase and lipase =< 1.5 ULN; subjects with amylase or lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of pancreatitis
+Serum lipase and amylase =< 1.5 x ULN.
+Serum lipase > 1.5 x ULN
+Serum lipase and amylase =< 1.5 x ULN.
+Lipase =< 1.5 x ULN
+Serum amylase/lipase =< 1.5 x ULN
+Serum amylase =< 2 x ULN
+Serum lipase =< ULN
+Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
+Lipase =< 3 x ULN
+Serum amylase =< ULN
+Lipase =< ULN
+FULL STUDY INCLUSION CRITERIA: Amylase and lipase =< 1.5 x ULN
+Lipase < 2 ULN
+Note: in the absence of clinical symptoms of pancreatitis, elevations of amylase or lipase are not contraindications to therapy on this trial
+Serum amylase and lipase =< 2 x ULN
+Serum amylase and lipase =< 1.5 x ULN
+Serum amylase and lipase =< 1.5 x institutional ULN
+Normal serum lipase and amylase (per institutional normal values)
+Serum amylase =< 2 x ULN
+Serum lipase =< ULN
+History of pancreatitis or history of increased amylase or lipase that was due to pancreatitis
+Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
+CAPMATINIB INCLUSION CRITERIA: Serum amylase =< grade 2 and asymptomatic; patients with grade 1 or 2 serum amylase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)
+CAPMATINIB INCLUSION CRITERIA: Serum lipase =< ULN
+CERITINIB INCLUSION CRITERIA: Serum lipase =< ULN
+CERITINIB EXCLUSION CRITERIA: History of pancreatitis, or history of increased amylase or lipase that was due to pancreatic disease
+Serum amylase =< 2 x ULN
+Serum lipase =< ULN
+Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
+Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
+Have normal pancreatic status as defined by the following criterion: a. Serum lipase and amylase ? 1.5 × ULN
+Amylase =< 2 X ULN
+For patients being screened for Group 2, asymptomatic serum amylase > CTCAE Grade 2 (1.5-2.0 x ULN). Patients with Grade 1 or Grade 2 serum amylase at the beginning of the study must be confirmed to have no signs or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)
+For patients being screened for Group 2: Serum lipase > ULN
+Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.
+Within 4 days prior to the first dose of cabozantinib: Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
+Serum amylase =< 2 x ULN
+Serum lipase =< ULN
+Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
+Serum lipase and amylase =< 1.5 x ULN
+Serum lipase =< 2 x ULN
+Serum amylase =< 2 x ULN
+Lipase < 2.0 x ULN; no radiologic or clinical evidence of pancreatitis
+Serum amylase =< ULN
+Serum lipase =< ULN
+Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
+Serum lipase and amylase =< 1.5 x ULN
+Asymptomatic serum amylase grade > 2 (1.5-2.0 x ULN). Patients with grade 1 or grade 2 serum amylase at the beginning of the study must be confirmed to have no signs or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)
+Serum lipase > ULN
+Serum amylase =< ULN
+Serum lipase =< ULN
+Within 14 days prior to first dose of study drug treatment: Amylase and lipase =< 1.5 x ULN
+Within 7 days before the first dose of cabozantinib: Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
+Amylase < ULN
+Lipase < ULN
+Serum amylase and lipase within normal limits
+Lipase =< 1.5 x the ULN
+Amylase =< 1.5 x the ULN
+Within 14 days prior to registration: Serum amylase =< 1.5 x institution’s ULN
+Within 14 days prior to registration: Serum lipase =< 1.5 x institution’s ULN
+Amylase and/or lipase =< 1.5 x ULN, obtained =< 7 days prior to registration
+Lipase < 2.0 x ULN; no radiologic/clinical evidence of pancreatitis
+Lipase > 1.5 ULN; participants with lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis
+Amylase > 1.5 ULN; participants with amylase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis
+Lipase < 1.5 times the ULN
+Fasting serum amylase =< 2 x institutional ULN
+Fasting serum lipase =< institutional ULN
+Patients must have a lipase and amylase performed within 7 days prior to sub-study registration
+Serum amylase and lipase =< 1.5 x the ULN
+Amylase =< 1.5 x ULN
+Lipase =< 1.5 x ULN
+Within 14 days of subject registration: Serum amylase =< 2 x ULN and serum lipase within normal limits
+Amylase or lipase within normal limit (per institutional standards)
+Lipase =< 1.5 x upper limit of normal (ULN)
+Amylase (0-160 U/L) and lipase (0-130 U/L) levels within 1.5 times the range of normal
+Serum amylase =< ULN
+Serum lipase =< ULN
+Amylase and lipase =< 1.5 x the upper limit of normal
+Patients must have a lipase, amylase, TSH with reflex free T3/T4 performed within 7 days prior to sub-study registration; (Note: For the Canadian sites, testing for lipase only is acceptable)
+Amylase and lipase <=ULN [Applies to Phase 2].
+Lipase < 2 X the upper limit of normal (ULN) and no radiologic or clinical evidence of pancreatitis
+Lipase performed within 28 days of randomization must be less than or equal to 1.5 x ULN for the lab.
+Lipase =< 1.5 x the ULN
+Serum amylase =< ULN
+Serum lipase =< ULN
+Amylase and lipase ? 2X upper limit of normal
+Lipase ? 1.5 x ULN
+Asymptomatic serum amylase or lipase > Grade 2
+Serum amylase or serum lipase CTCAE grade ? 1 with signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g. elevated P-amylase, abnormal imaging findings of pancreas, etc)
+Adequate pancreatic function, defined as amylase and lipase less than or equal to 1.5 X ULN
+Amylase and lipase =< 2 times institutional ULN for age
+Obtained =< 7 days prior to registration:\r\nSerum amylase and lipase =< 1.5 x upper limit of normal (ULN)
+Lipase =< 1.5 x the ULN
+Lipase less than or equal to 2 x ULN
+Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.
+Serum lipase and amylase =< 2.5 x ULN; NOTE: if subject has tumor involvement in the liver =< 3 x ULN
+Lipase =< 1.5 x the ULN
+Serum amylase =< ULN
+Serum lipase =< ULN
+Lipase =< 1.5 x the ULN
+Amylase =< 1.5 x the ULN
+Serum lipase/amylase ?1.5 x ULN
+Lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
+Serum amylase > 1.5 x ULN or serum lipase > 1.5 x ULN.
+Amylase and lipase equal to, or less than, the institutional ULN
+PART B: Serum lipase =< 1.5 X ULN
+PART B: Serum amylase =< 1.5 X ULN
+Normal serum amylase =< (ULN) OR normal
+Serum lipase =< ULN
+Obtained =< 7 days prior to registration: Serum lipase =< 1.5 x ULN
+Serum lipase ? 2 x ULN
+Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
+Serum amylase =< 1.5 x ULN
+Serum lipase =< 1.5 x ULN
+Have Amylase =< 2.5x ULN
+Amylase and lipase levels =< ULN
+Amylase and lipase =< 1.5 x ULN
+Amylase < 1.5 times ULN
+Amylase and lipase < 1.5 x of ULN
+Serum amylase or lipase <1.5 x ULN;
+Amylase and lipase =< 2 x ULN
+Amylase and lipase ? 2.5 x ULN (? 5 x ULN for subjects with pancreas involvement with tumor)
+Lipase levels < 1.5 X ULN
+Amylase levels < 1.5 X ULN
+Serum amylase =< ULN
+Serum lipase =< ULN
+Amylase =< 1.5 x the ULN
+Lipase =< 1.5 x the ULN
+Serum lipase ? 3 x ULN and serum amylase within the normal range
+Serum lipase ? 3 x ULN and serum amylase within the normal range
+Lipase and amylase =< 1.5 x ULN
+Lipase</=1.5 times the ULN
+Serum lipase > normal limits for the institution
+Asymptomatic serum amylase > grade 2
+Lipase =< 1.5 x ULN
+Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
+Serum amylase =< 2 x ULN
+Serum lipase =< 1 x ULN
+History of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
+Lipase and amylase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
+Serum amylase =< upper limit of normal (ULN) (if > ULN, confirm pancreatic amylase < 1 .1ukat/L and serum lipase < ULN)
+Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis
+Serum amylase and lipase within normal limits
+Amylase =< 1.5 x ULN
+Lipase =< 1.5 x ULN
+Amylase and lipase ? 1.5 x ULN
+History of pancreatitis, or amylase > ULN
+History of lipase > ULN
+Serum amylase =< ULN
+Serum lipase =< ULN
+Amylase and Lipase < 1.5 x normal for age.
+Lipase =< 1.5 x the ULN
+Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitis
+>= grade 2 lipase increased (> 1.5 x ULN)
+Any history of an immune-related Grade 4 adverse event attributed to prior CIT (other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase)
+Patients with a prior or current history of a second malignancy, impaired GI function, history of pancreatitis or increased amylase or lipase, known diagnosis of HIV, and clinically significant cardiac disease were excluded.
+Amylase =< 1.5 x ULN
+Lipase =< 1.5 x ULN
+Serum amylase =< 2 x ULN
+Serum lipase =< ULN
+Patient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease
+Lipase =< 1.5 x the ULN
+Lipase =< 1.5 ULN
+Lipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.
+Lipase ?1.5×ULN and amylase ?1.5×ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.
+At least two episodes of acute pancreatitis in the past 12 months; acute pancreatitis is defined any 2 of the following: (1) typical upper abdominal pain; (2) elevation in serum amylase or lipase >= 3 times upper limit of normal; (3) features of acute pancreatitis on cross-sectional imaging
+Serum lipase =< 1.5 x ULN
+Lipase must be <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis and cholecystitis.